What's new in cardiac cell therapy? Allogeneic bone marrow stromal cells as "universal donor cells".
Cardiac cell therapies offer distinct and exciting advantages over current treatments to prevent postinfarction heart failure because they can reverse ventricular remodeling and improve function, but only if the implanted stem cells contribute biological functions and achieve prolonged engraftment within the hostile environment of the damaged heart. Unfortunately, function is diminished in autologous stem cells isolated from older patients and those with comorbidities, and so clinical trials testing the implantation of healthy, allogeneic bone marrow-derived stromal cells (MSCs) isolated from young donors are currently underway. MSCs are unique because, in addition to exerting paracrine effects that restore blood flow and recruit endogenous stem cells to the infarct, they exhibit immune-modulating properties in culture that-if retained after allogeneic implantation-imply the cells may escape immune recognition within the heart. At present, the scope of MSC immune modulation after implantation is unclear.
Division of Cardiovascular Surgery and Department of Surgery, Toronto General Research Institute and University of Toronto, Toronto, Ontario, Canada.
Heather Y McDonald
HY
Kinkaid
Xi-Ping
XP
Huang
Ren-Ke
RK
Li
Richard D
RD
Weisel
D016026:Bone Marrow Transplantation; D064987:Cell- and Tissue-Based Therapy; D006321:Heart; D006801:Humans; D009206:Myocardium / Q000166:cytology*; D017154:Stromal Cells / Q000637:transplantation; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous